Bobby Cook
Medicare beneficiaries taking GLP-1 drugs for weight loss will soon pay a flat $50 monthly copay under a new federal pilot, cutting a cost that has often run into the hundreds of dollars.
Bridge Program Mechanics and Timeline
The Centers for Medicare & Medicaid Services is rolling out the Medicare GLP-1 Bridge, a demonstration program that starts July 1 and continues through December 31, 2027. It operates outside standard Medicare Part D structures, meaning the $50 payment will not count toward annual deductibles, out of pocket maximums, or the Medicare Prescription Payment Plan. It also will not trigger low income subsidy benefits. Every participant pays the same flat rate for the duration of the pilot, regardless of dosage or plan.
Chris Klomp, director of Medicare and chief counselor at the Department of Health and Human Services, framed the initiative as an effort to standardize access. He said the program is meant to make obtaining these medications more predictable and consistent across Medicare, language that signals CMS wants to avoid the patchwork coverage that has characterized GLP-1 access until now.
Historical Coverage Gap Being Addressed
Medicare has never covered drugs prescribed solely for weight loss. GLP-1s such as semaglutide and tirzepatide products have only qualified for coverage when prescribed for type 2 diabetes, cardiovascular disease, and a handful of other diagnosed conditions. That left a substantial population of beneficiaries with obesity, but without a qualifying comorbidity on the approved list, paying full price. The Bridge program is a targeted, time limited fix rather than a permanent policy change, and CMS has structured it explicitly as a demonstration, which means its continuation past 2027 is not guaranteed.
Estimates of the eligible population vary. KFF, using 2023 data, puts the potential pool at 3.8 million Medicare beneficiaries. Klomp has offered a more conservative figure, describing
Christina Shaw
Roberto Anderson
Franklin Gonzales